A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Ahead of this weekend's Super Bowl, some good news for the athletes: NFL players are largely avoiding opioid-based pain ...

The number of anesthesiology residents applying to pain medicine decreased 45 percent from 2019 to 2023, according t ...

Dr. Ilana Etelzon Integrates CompuFlo® Epidural System into Practice Following Positive Clinical ExperienceROSELAND, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Inc. (NYSE: MLSS), a leading developer of ...

Anesthesia remains a dynamic industry as leaders explore new methods of opioid-free pain management and expand into new care settings. Christina Menor, MD, president-elect of the California Society of ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

We welcome O’Ryan and colleagues’ introspective tone and call for a “global conversation” on academia’s role in healthcare.1 Their article resonates with our thoughts and experiences in pain ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

High bilirubin levels increase the risk of developing bilirubin gallstones—a type of gallstone more prevalent in Sickle Cell ...

The study found that between 2019 and 2023, there was an overall 45% decline in anesthesia-based applicants to pain medicine fellowships.

The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...

From less independence to higher pay, physicians often have to make several tradeoffs when deciding between employment and private practice. Seven orthopedic and spine specialists told Becker's some ...